Yogin Patel, MD
Ophthalmology · Conyers, GANPI 1457606816
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,818 of the $33,737 with a category attached, or 64.7%. 20 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 58.0% of the total. 2025 is the largest year on record at $19,195, 3.6 times the $5,348 reported in 2019. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $122.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$20K
- F. Hoffmann-la Roche AG$4K
- Notal Vision, Inc.$2K
- Genentech USA, Inc.$1K
- Alimera Sciences, Inc.$1K
- AbbVie$1K
- plus $4K from 14 others
Across 17 payments — averaging $37.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$630
What the payments were for
- Speaking & faculty fees$21,81865%
- Travel & lodging$1,5595%
- Food & beverage$10,36031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 79 | $19,571 |
| F. Hoffmann-la Roche AG | 1 | $4,139 |
| Notal Vision, Inc. | 10 | $1,814 |
| Genentech USA, Inc. | 46 | $1,469 |
| Alimera Sciences, Inc. | 30 | $1,302 |
| AbbVie(2 entities) | 38 | $1,163 |
| Astellas Pharma US Inc | 15 | $770 |
| Alcon | 9 | $733 |
| ANI Pharmaceuticals, Inc. | 13 | $568 |
| Apellis Pharmaceuticals, Inc. | 6 | $496 |
| Novartis | 7 | $374 |
| Bausch & Lomb Americas Inc. | 5 | $355 |
| Eyepoint US, Inc. | 5 | $209 |
| Sight Sciences, Inc. | 1 | $147 |
| Biogen | 2 | $140 |
| Rxsight Inc | 1 | $125 |
| Regeneron | 1 | $123 |
| Samsara Vision | 1 | $114 |
| Coherus Oncology, Inc. | 4 | $105 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$17,798
- Lucentis$4,280
- Iluvien$870
- NGENUITY$413
- VABYSMO$391
- XIPERE$288
- SUSVIMO$283
- OZURDEX$273
- Syfovre$265
- EYLEA$244
- Clareon$147
- OMNI(R) SURGICAL SYSTEM (US)$147
- VISUDYNE$145
- YUTIQ$128
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Izervay$125
- PURIFIED CORTROPHIN GEL$120
- Implantable Miniature Telescope$114
- BYOOVIZ$112
How this compares
$33,737 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 201 | $8,863 |
| ProlensaBromfenac Sodium | 17 | $6,002 |
| Ketorolac Tromethamine | 97 | $3,723 |
| Brimonidine Tartrate | 35 | $1,002 |
| Ciprofloxacin Hcl | 86 | $946 |
| Atropine Sulfate | 17 | $699 |
| Timolol Maleate | 23 | $396 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $364 |
| Cyclopentolate Hcl | 13 | $258 |
| Latanoprost | 33 | $162 |
| Dorzolamide Hcl | 11 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $20 | $6,00217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Conyers
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
- Evan SchoenbergAtlanta$130K
- Niraj DesaiCumming$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.